Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: A population-based cohort study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhou, Wenjing ^a   Jirström, Karin ^b   Amini, Rose Marie ^a   Fjällskog, Marie Louise ^a   Sollie, Thomas ^c   Lindman, Henrik ^a   Sørlie, Therese ^d   Blomqvist, Carl ^e   Wärnberg, Fredrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; TISSUE CHARACTERIZATION; TUMOR INVASION;

AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84886497066     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-512     Document Type: Article

References (21)

1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-47. 10.1093/annonc/mdr304, 3144634, 21709140.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
4. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24(9):2206-23. 10.1093/annonc/mdt303, 3755334, 23917950.
5. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006, 8:R61. 10.1186/bcr1613, 1779498, 17069663.
6. Muggerud AA, Sørlie T, Hallet M, Johnsen H, Zhou W, Tahmasebpoor S, Amini R-M, Botling J, Børresen-Dale A-L, Wärnberg F. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 2010, 4(4):357-368. 10.1016/j.molonc.2010.06.007, 20663721.
7. Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S, Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010, 2010(41):162-77. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
8. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker Expression and Risk of Subsequent Tumours After Initial Ductal Carcinoma In Situ Diagnosis. J Natl Cancer Inst. 2010, 102:627-637. 10.1093/jnci/djq101, 2864293, 20427430.
9. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. J Natl Cancer Inst 2013, 105(10):701-10. 10.1093/jnci/djt067, 3653823, 23641039.
10. Zhou W, Jirström K, Johansson C, Amini R-M, Blomqvist C, Agbaje O, Wärnberg F. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer. 2010, 10:653. 10.1186/1471-2407-10-653, 3001723, 21118480.
11. Wärnberg F, Amini R-M, Goldman M, Jirström K. Quality aspects on the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast. Histopathology 2008, 53(6):642-649. 10.1111/j.1365-2559.2008.03156.x, 19076680.
12. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
13. Wärnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001, 85(6):869-74. 10.1054/bjoc.2001.1995, 2375068, 11556839.
14. Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011, 11:292. 10.1186/1471-2407-11-292, 3157458, 21749714.
15. Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A. Prognostic applications of gene expression signatures in breast cancer. Oncology. 2009, 77(Suppl 1):2-8.
16. Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol). 2012, 24(3):183-9. 10.1016/j.clon.2011.09.008, 21958729.
17. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012, 106(6):1160-1165. 10.1038/bjc.2012.41, 3304413, 22361634.
18. Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer. 2011, 2:232-61. 3088863, 21552384.
19. Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012, 23(12):2997-3006. 10.1093/annonc/mds586, 23166150.
20. Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, Voorhorst F, Baak JP. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 2012, 61(6):1134-44. 10.1111/j.1365-2559.2012.04329.x, 22963617.
21. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007, 38(2):197-204. 10.1016/j.humpath.2006.08.017, 17234468.